Cargando…
Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with C...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589012/ https://www.ncbi.nlm.nih.gov/pubmed/34431085 http://dx.doi.org/10.1111/bjh.17790 |
_version_ | 1784598615065362432 |
---|---|
author | Venturini, Cristina Houldcroft, Charlotte J. Lazareva, Arina Wegner, Fanny Morfopoulou, Sofia Amrolia, Persis J. Golwala, Zainab Rao, Anupama Marks, Stephen D. Simmonds, Jacob Yoshikawa, Tetsushi Farrell, Paul J. Cohen, Jeffrey I. Worth, Austen J. Breuer, Judith |
author_facet | Venturini, Cristina Houldcroft, Charlotte J. Lazareva, Arina Wegner, Fanny Morfopoulou, Sofia Amrolia, Persis J. Golwala, Zainab Rao, Anupama Marks, Stephen D. Simmonds, Jacob Yoshikawa, Tetsushi Farrell, Paul J. Cohen, Jeffrey I. Worth, Austen J. Breuer, Judith |
author_sort | Venturini, Cristina |
collection | PubMed |
description | Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV(+) haematological clones that are lost on successful treatment. |
format | Online Article Text |
id | pubmed-8589012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85890122021-11-19 Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV Venturini, Cristina Houldcroft, Charlotte J. Lazareva, Arina Wegner, Fanny Morfopoulou, Sofia Amrolia, Persis J. Golwala, Zainab Rao, Anupama Marks, Stephen D. Simmonds, Jacob Yoshikawa, Tetsushi Farrell, Paul J. Cohen, Jeffrey I. Worth, Austen J. Breuer, Judith Br J Haematol Haematological malignancy–Biology Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV(+) haematological clones that are lost on successful treatment. John Wiley and Sons Inc. 2021-08-24 2021-10 /pmc/articles/PMC8589012/ /pubmed/34431085 http://dx.doi.org/10.1111/bjh.17790 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Haematological malignancy–Biology Venturini, Cristina Houldcroft, Charlotte J. Lazareva, Arina Wegner, Fanny Morfopoulou, Sofia Amrolia, Persis J. Golwala, Zainab Rao, Anupama Marks, Stephen D. Simmonds, Jacob Yoshikawa, Tetsushi Farrell, Paul J. Cohen, Jeffrey I. Worth, Austen J. Breuer, Judith Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title | Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title_full | Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title_fullStr | Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title_full_unstemmed | Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title_short | Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV |
title_sort | epstein–barr virus (ebv) deletions as biomarkers of response to treatment of chronic active ebv |
topic | Haematological malignancy–Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589012/ https://www.ncbi.nlm.nih.gov/pubmed/34431085 http://dx.doi.org/10.1111/bjh.17790 |
work_keys_str_mv | AT venturinicristina epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT houldcroftcharlottej epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT lazarevaarina epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT wegnerfanny epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT morfopoulousofia epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT amroliapersisj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT golwalazainab epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT raoanupama epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT marksstephend epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT simmondsjacob epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT yoshikawatetsushi epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT farrellpaulj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT cohenjeffreyi epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT worthaustenj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv AT breuerjudith epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv |